anlotinib + docetaxel

Anlotinib + docetaxel is a combination therapy used primarily in the treatment of advanced non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), particularly as a second-line or later option after failure of first-line treatments. Anlotinib is an oral, novel multitarget tyrosine kinase inhibitor that inhibits angiogenesis and tumor progression by targeting multiple kinases including VEGFR, PDGFR, FGFR-2, and c-Kit. It blocks tumor growth by inhibiting new blood vessel formation (angiogenesis) and has demonstrated antitumor effects in several cancers. Docetaxel is a semisynthetic taxoid antineoplastic agent that stabilizes microtubules by promoting their assembly from tubulin dimers and preventing depolymerization, thereby disrupting mitosis and inducing apoptosis in cancer cells. The combination has shown improved clinical effectiveness over monotherapy with either agent alone, with enhanced survival rates and manageable safety profiles[1][4][5].